Bonesupport Holding AB (publ) (BONEX.ST) Stock Analysis
A De Novo-protected, antibiotic-eluting bioceramic platform is turning complex bone infection care into single-stage surgery—scaling fast in the U.S. with software-like margins, but tethered to FDA/CMS timing and execution.
Overview
Bonesupport is a leading orthobiologics company commercializing CERAMENT, a patented injectable bio-ceramic bone graft substitute designed to manage complex bone voids from trauma, infection (osteomyelitis), and revision surgeries. Revenues are driven by CERAMENT BVF and, increasingly, the antibiotic-eluting formulations CERAMENT G and CERAMENT V—among the first injectable drug-eluting bone graft substitutes authorized for local gentamicin and (pending U.S. approval) vancomycin delivery. The platform enables a shift toward single-stage surgery, reducing hospital stay, surgical burden, and overall cost of care. The U.S. is the primary growth engine after 2022 FDA approval of CERAMENT G; by 2025 the company had placed products in 140+ of 250 U.S. Level 1 trauma centers, supporting FY2025 net sales of SEK 1,175m (+31% reported; +40% CER) with ~93% gross margins and expanding operating leverage.